PHGE Quote, Financials, Valuation and Earnings

IM Cannabis Corp. has a net margin of -- compared to BiomX, Inc.'s net margin of -27.9%. BiomX, Inc.'s return on equity of -160.84% beat IM Cannabis Corp.'s return on equity of -135.96%.

BiomX, Inc. has a consensus price target of $399.00, signalling upside risk potential of 8264.78%. On the other hand IM Cannabis Corp. has an analysts' consensus of -- which suggests that it could grow by 234.82%. Given that BiomX, Inc. has higher upside potential than IM Cannabis Corp., analysts believe BiomX, Inc. is more attractive than IM Cannabis Corp..

BiomX, Inc. has a beta of 1.558, which suggesting that the stock is 55.818% more volatile than S&P 500. In comparison IM Cannabis Corp. has a beta of 2.180, suggesting its more volatile than the S&P 500 by 117.961%.

BiomX, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IM Cannabis Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BiomX, Inc. pays -- of its earnings as a dividend. IM Cannabis Corp. pays out -- of its earnings as a dividend.

BiomX, Inc. quarterly revenues are --, which are smaller than IM Cannabis Corp. quarterly revenues of $10.1M. BiomX, Inc.'s net income of -$9.2M is lower than IM Cannabis Corp.'s net income of -$2.8M. Notably, BiomX, Inc.'s price-to-earnings ratio is -- while IM Cannabis Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BiomX, Inc. is -- versus 0.17x for IM Cannabis Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IR-Med, Inc. has a net margin of -- compared to BiomX, Inc.'s net margin of --. BiomX, Inc.'s return on equity of -160.84% beat IR-Med, Inc.'s return on equity of --.

BiomX, Inc. has a consensus price target of $399.00, signalling upside risk potential of 8264.78%. On the other hand IR-Med, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that BiomX, Inc. has higher upside potential than IR-Med, Inc., analysts believe BiomX, Inc. is more attractive than IR-Med, Inc..

BiomX, Inc. has a beta of 1.558, which suggesting that the stock is 55.818% more volatile than S&P 500. In comparison IR-Med, Inc. has a beta of 2.696, suggesting its more volatile than the S&P 500 by 169.614%.

BiomX, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IR-Med, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BiomX, Inc. pays -- of its earnings as a dividend. IR-Med, Inc. pays out -- of its earnings as a dividend.

BiomX, Inc. quarterly revenues are --, which are smaller than IR-Med, Inc. quarterly revenues of --. BiomX, Inc.'s net income of -$9.2M is lower than IR-Med, Inc.'s net income of -$701K. Notably, BiomX, Inc.'s price-to-earnings ratio is -- while IR-Med, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BiomX, Inc. is -- versus -- for IR-Med, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pluri, Inc. has a net margin of -- compared to BiomX, Inc.'s net margin of -1940.51%. BiomX, Inc.'s return on equity of -160.84% beat Pluri, Inc.'s return on equity of -5662.45%.

BiomX, Inc. has a consensus price target of $399.00, signalling upside risk potential of 8264.78%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 268.1%. Given that BiomX, Inc. has higher upside potential than Pluri, Inc., analysts believe BiomX, Inc. is more attractive than Pluri, Inc..

BiomX, Inc. has a beta of 1.558, which suggesting that the stock is 55.818% more volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.575, suggesting its less volatile than the S&P 500 by 42.476%.

BiomX, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BiomX, Inc. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.

BiomX, Inc. quarterly revenues are --, which are smaller than Pluri, Inc. quarterly revenues of $316K. BiomX, Inc.'s net income of -$9.2M is lower than Pluri, Inc.'s net income of -$6.1M. Notably, BiomX, Inc.'s price-to-earnings ratio is -- while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BiomX, Inc. is -- versus 17.83x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Raphael Pharmaceutical, Inc. has a net margin of -- compared to BiomX, Inc.'s net margin of --. BiomX, Inc.'s return on equity of -160.84% beat Raphael Pharmaceutical, Inc.'s return on equity of --.

BiomX, Inc. has a consensus price target of $399.00, signalling upside risk potential of 8264.78%. On the other hand Raphael Pharmaceutical, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that BiomX, Inc. has higher upside potential than Raphael Pharmaceutical, Inc., analysts believe BiomX, Inc. is more attractive than Raphael Pharmaceutical, Inc..

BiomX, Inc. has a beta of 1.558, which suggesting that the stock is 55.818% more volatile than S&P 500. In comparison Raphael Pharmaceutical, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

BiomX, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Raphael Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BiomX, Inc. pays -- of its earnings as a dividend. Raphael Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

BiomX, Inc. quarterly revenues are --, which are smaller than Raphael Pharmaceutical, Inc. quarterly revenues of --. BiomX, Inc.'s net income of -$9.2M is lower than Raphael Pharmaceutical, Inc.'s net income of -$255K. Notably, BiomX, Inc.'s price-to-earnings ratio is -- while Raphael Pharmaceutical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BiomX, Inc. is -- versus -- for Raphael Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.